El año pasado, Sinovac Biotech Ltd generó 149.22M USD en su segmento con mejor rendimiento, Enterovirus 71 vaccines. Mainland China realizó la mayor aportación, representando 261.18M USD el año pasado.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Enterovirus 71 vaccines

Inactivated hepatitis vaccines

Mumps vaccines

Influenza vaccines

H5N1 vaccines

Other

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Enterovirus 71 vaccines

149.22M(60.65%)

162.54M(70.78%)

121.28M(69.57%)

35.14M(48.52%)

--(--)

Inactivated hepatitis vaccines

57.95M(23.55%)

63.43M(27.62%)

37.85M(21.71%)

20.60M(28.44%)

49.42M(73.30%)

48.45M(76.99%)

47.20M(65.76%)

39.95M(81.18%)

26.94M(47.39%)

Mumps vaccines

19.73M(8.02%)

1.66M(0.72%)

1.67M(0.96%)

477.00K(0.66%)

1.47M(2.18%)

2.15M(3.42%)

1.68M(2.34%)

--(--)

Influenza vaccines

19.14M(7.78%)

2.03M(0.88%)

13.54M(7.77%)

9.83M(13.57%)

12.67M(18.80%)

12.13M(19.28%)

12.16M(16.94%)

9.19M(18.68%)

29.90M(52.61%)

H5N1 vaccines

--(--)

6.39M(8.82%)

3.85M(5.71%)

201.00K(0.32%)

10.74M(14.96%)

--(--)

Other

--(--)

73.41K(0.15%)

--(--)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Mainland China

Foreign countries

Hong Kong

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Mainland China

261.18M(67.66%)

297.00M(82.19%)

402.96M(85.70%)

1.07B(72.94%)

10.90B(56.28%)

365.62M(71.60%)

227.11M(92.30%)

215.12M(93.67%)

172.90M(99.17%)

71.18M(98.28%)

66.78M(99.06%)

61.95M(98.45%)

70.65M(98.43%)

48.20M(97.93%)

56.41M(99.24%)

Foreign countries

124.83M(32.34%)

64.37M(17.81%)

67.21M(14.30%)

398.74M(27.06%)

8.47B(43.72%)

145.00M(28.40%)

18.94M(7.70%)

14.53M(6.33%)

1.45M(0.83%)

--(--)

Hong Kong

--(--)

1.25M(1.72%)

635.00K(0.94%)

977.00K(1.55%)

1.13M(1.57%)

1.02M(2.07%)

434.76K(0.76%)